



Improving Lives With Innovative Plant-based Medicine

August 2022

Disclaimer

The information contained in this presentation and any accompanying oral presentation (“Presentation”) is being supplied to you by MGC Pharmaceuticals Limited on behalf of itself and its subsidiaries (together, “MGC”). By accepting this Presentation, you agree to be bound by the following terms.

The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Market Act 2000 (FSMA).

This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with MGC’s other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of MGC nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities.

This Presentation is exempt from the general restriction set out in section 21 of FSMA on the communication of financial promotions.

This communication is exempt under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) on the grounds that it is made or directed only to: (a) persons having professional experience in matters relating to investments within the definition of investment professionals in Article 19(5) of the Order; and (b) recipients who are high net worth bodies corporate, unincorporated associations, and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; (all such persons together being referred to as “Relevant Persons”). Persons of any other description, including those that do not have professional experience in matters relating to investments, should not rely or act upon this Presentation, and the controlled investment and controlled activity to which this Presentation relates will only be available to Relevant Persons. If a person is unsure whether they would be classed as a Relevant Person, then they should seek independent legal advice or advice from an investment professional.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists of summarised information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in MGC is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

No Liability

The information contained in this Presentation has been prepared in good faith by MGC, however no guarantee, representation or warranty, expressed or implied is, or will be made, by any person (including MGC and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, MGC and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of

or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

MGC, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Forward looking statements

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute “forward-looking statements” or statements about “future matters”, the information reflects MGC’s intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, MGC disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MGC’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of MGC only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning MGC and its subsidiaries. The forward-looking information contained in the Presentation is expressly qualified by this cautionary statement.

This Presentation must not be distributed, published, reproduced or otherwise made available to any person, in whole or in part, for any purposes whatsoever with addresses the United States, its territories or possessions or in any other jurisdiction outside of Australia or the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction and you undertake to indemnify MGC for any loss or damage incurred as a result of your breach of this undertaking.



UK - Corporate HQ & LSE Listing

Slovenia – R&D Centre, GMP IMP Facility

Malta – New, large-scale
Manufacturing Facility

Israel – Clinical Research Management

Australia – ASX Listing

MGC Pharma: The Company

MGC Pharma (MXC: LSE, ASX) is a Global Bio-Pharma company with headquarters in the United Kingdom.

We are focused on the production of Plant-based medicines for diseases including:

- Epilepsy
- Dementia
- Alzheimer's and
- COVID-19



MGC Pharma: Our Vision

‘Our vision is to have a global impact on undertreated medical conditions and diseases, wielding the power of plant-based medicines in novel combinations by using innovative technology to harness knowledge and science to achieve our “Nature to Medicine” strategy.’

Roby Zomer
Co-Founder, Director & CEO



MGC Pharma's Foundation Principles and Values

Innovative Plant-based Medicine

Using the earth's natural elements, science, and our experienced research team's understanding of cannabinoids, to provide patients with cutting-edge pharmaceuticals to treat disease processes and symptoms by improving overall well-being. We focus on combining natural and plant-based active ingredients to create next-generation medications.

ESG and Core Values

Our team operates with an established code of principles. We chose our partners carefully to ensuring the quality of raw materials are of a high standard from ethical and sustainable sources.

Diversified Revenue Streams



Plant-based Medicine Innovation

The Company's primary focus is research and clinical trials to support the creation of breakthrough plant-based medicines. Holding IP protection combined with high-profit margins, products are developed to achieve health insurance coverage for our product within their territories. Innovative Phyto Medicines should represent 80% of MGC's turnover and value.



Generic formulations


A secondary focal point, currently producing the bulk of MGC's revenues, is relying on established and registered formulations. Generic formulations create viable entry points into new markets, acting as an effective foothold until proprietary products can enter all markets.



Unique Market Position

Rapidly expanding global pharma market for plant-based medicines provides new opportunities for MGC growth and development of new generation of plant-based medications

**Plant-based
Bio Pharma**




ReportLinker. (2022, March 4). Pharmaceuticals Global Market Report 2022. Globalnewswire.com.


ReportLinker. (2022, June 7). Herbal Medicine Market Research Report by Product, Form, Source, Type of Medicinal Plant, Indication, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19. Globalnewswire.com



Global Cumulative Sales have reached c.£2.6m over the last 12 months



Research and Development – Product Pipeline




Our flagship line of products is developed to fight the most demanding conditions.



Cimetra™

ANTI INFLAMMATORY



CannEpil™

REFRACTORY EPILEPSY

**Investigational Medical Product (IMP) IMPs are medical products designed and manufactured for clinical trials, and they are made available to patients via early access schemes.*



Flagship Product – COVID19 & Anti Inflammatory

CimetrA™

- Based on natural ingredients including Curcumin and Boswellia serrata.
- Uses an enhanced delivery system technology, a platform to deliver natural ingredients more effectively in higher concentrations to the cells, improving the bioavailability of natural ingredients.
- Delivered via the nanoparticle delivery system it has been clinically proven effective in arresting the cytokine storm in COVID-19 patients.
- Successfully met all primary and secondary study endpoints (100% of patients in the treatment group) and all FDA requirements for diversity of patients.
- None of the patients in the treatment group required additional oxygen, mechanical ventilation, or admission to intensive care.
- Results from a Pre-clinical In-vitro study indicate shows wide- ranging application as an anti-inflammatory treatment, through the modulation of the production of pro-inflammatory cytokines.
- One of the key findings of the current study was the effectively blocking the IL-32mRNA expression, the pro-inflammatory cytokine related to Rheumatoid Arthritis, Inflammatory bowel disease, Asthma, Psoriasis and Chronic obstructive pulmonary disease.
- **IP Protected (IP Number – SIPO 26055).**

ANTI INFLAMMATORY



Formulation: Combination of Curcumin and Boswellia Serrata.

Route of administration : Medical oral spray

Flagship Product – Drug Resistant Epilepsy

CannEpil®

- Phytomedicine based on phytocannabinoids used as a treatment for drug-resistant (refractory) epilepsy.
- Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.
- The first legal medicinal cannabis product eligible for patients in Ireland and fully covered under Ireland's Primary Care Reimbursement Service as part of the country's Medicinal Cannabis Access Programme (MCAP).
- Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes.
- **IP Protected (IP Number – SIPO 26056).**

Target Market:

- Over 1,900,000 people have epilepsy in Europe (over 480,000 epilepsy patients in UK).
- Over 200,000 epilepsy patients in Australia.
- Approximately 25% of people with epilepsy have a drug-resistant (DRA) form.
- Estimated population at launch of marketing authorisation is over 200,000 people with DRA (in Europe and Australia).

REFRACTORY EPILEPSY



Formulation: Cannabidiol (CBD) 100 mg/mL
Delta-9-Tetrahydrocannabinol (THC) 5 mg/mL
Route of administration: Oral

Flagship Product - Dementia and Alzheimer's

CogniCann®

- Phytomedicine based on phytocannabinoids, used as a treatment for the symptoms associated with dementia and Alzheimer's.
- The efficacy was assessed using standard trial criteria.
- Patients in the Placebo group experienced a deterioration in their condition, compared with the stable neuropsychiatric profile of those patients treated with CogniCann®.
- Patients' aggressive behavior improved by 13%, compared with the Placebo Group, which improved by 4%.
- This important finding indicates not only improvement in the health status of the patients but also the improved quality of life of the families and caregivers taking care of dementia patients.

Target Market:

- Over 690,000 people with mild dementia in Europe (over 200,000 mild dementia patients in the UK).
- Over 135,000 mild dementia patients in Australia.
- Total estimated mild dementia population of 950,000 at marketing authorisation launch (in Europe and Australia).

ALZHEIMER'S

DEMENTIA




Formulation : Cannabidiol (CBD) and (-)-trans-r9-tetrahydrocannabinol (THC) in a 3:5 ratio, dissolved in MCT oil.

Route of administration : Medical oral spray

New Cannabinoid Medical Pipeline

IrniCann® - New drug

- The Glioblastoma research study, conducted between 2019-2022, initially used a formulation that included THC (delta-9-tetrahydrocannabinol), which was later replaced with Cannabigerol (**CBG**), which has no known psychotropic effects.
- The study demonstrated that MGC's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis (or cell death).
- With the research study's results demonstrating the cannabinoid treatment's viability, MGC Pharma is planning to undertake additional research to further demonstrate the formulation's efficacy as a treatment for Glioblastoma.



Glioblastoma



Formulation : Cannabidiol (CBD) and Cannabigerol (CBG) in a 3:1 ratio, dissolved in base formulation.

Route of administration : Tablets

MGC Pharma Generic Cannabinoid Formulations



MP 1:1
CBD: **25 mg/ml**
THC: **25 mg/ml**

MP 1:30
CBD: **100 mg/ml**
THC: **3.3 mg/ml**

MP 15:1
CBD: **1.7 mg/ml**
THC: **25 mg/ml**

MP 25T
THC: **25 mg/ml**



MP 100
CBD: **100 mg/ml**



ZAM Medical Data App

ZAM will enable patients to log their medical history and monitor medication use. Through the collection of patient data, the ZAM App will provide users with a more complete understanding of their health and treatment impacts.

The Artificial Intelligence (AI) Algorithm will use data collected from the ZAM App, including results from academic and clinical studies, to predict potential conflicting side effects from multiple treatments, as well as allowing users to order existing prescriptions, and provide the App user’s medical practitioner with a comprehensive set of data on treatment and medical history



Board of Directors

Highly qualified team with decades of relevant industry experience



Roby Zomer
Managing Director &
Chief Executive Officer

10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC's position as a leader in research and development, as well as ensuring top performance from our global operations.



Brett Mitchell
Executive Chairman

Mr Mitchell is a corporate finance executive with over 25 years of experience in the venture capital, equity capital markets, technology and resources sectors. He has been involved in the founding, financing and management of both private and publicly listed companies and was instrumental in the successful LSE listing for MGC Pharma in February 2021.



Dr. Stephen Parker
Senior Independent
Director & Chair of Board
Committees

Stephen Parker is a seasoned executive with over thirty years' experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategic consultant, a venture capitalist and a senior corporate financier. Stephen has a D.Phil. from Oxford University and an MBA from City University Business School.



Nativ Segev
Non-Executive Director

Previously CEO of a leading Medical Cannabis company with a large patient base, as well as over 10 years of experience in implementation, legislation and lobbying in the global medical cannabis industry, combined with over 15 years of experience in various executive roles.



Dr. Ross Walker
Non-Executive Director

Dr. Ross Walker is an eminent practicing cardiologist with a passion for people and health with 40 years' experience as a clinician. For the past 20 years he has been focusing on preventative cardiology & is one of Australia's leading preventative health experts.



Evan Hayes
Non-Executive Director

Highly experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Graduated with a Master of Science 1st Class Honours) from the National University of Ireland, Galway, and Bachelor of Science degree (Honours). Mr Hayes' has also won the Daniel O'Carroll Award for Scientific Research.



David Lim
Company Secretary

Mr Lim is a finance and corporate governance professional with over 15 years of experience working for ASX Listed companies. He has previously performed the role of Group CFO and Company Secretary at a number of ASX listed businesses including Equigold NL, Aurora Oil and Gas and Elixir Petroleum.

Officers – Expert Management Team

Leaders in the pharma and medical cannabis space with unparalleled expertise



Yifat Steuer
Officer & Chief of Staff

Yifat is qualified as a chartered accountant with Deloitte. Yifat has over 20 Years of experience as a well-versed CFO ranging from global blue-chip companies (Johnson & Johnson and GlaxoSmithKline) to hands-on implementation in SMEs and start-ups. Yifat has a proven track record in pharmaceuticals, manufacturing, logistics, distribution, medical technology, and digital health industries.



Sasha Friedman
Chief Operational Officer

Ms. Friedman has 12 years of experience in Business Process Design and implementation as a Senior Consultant for Deloitte and a Project Manager in Tel-Aviv-Jaffa municipality. Ms. Friedman has experience in implementing business solutions in various industries for Enterprise and SMB organizations globally and leading cross-sectional teams.



Angela-Marie Graham
Chief Financial Officer

Angela-Marie is a qualified ACCA Accountant with over 20 years' experience and is accustomed to working with the C suite, the Board and external investors. She has worked in practice and industry in a number of industries including Telecoms (BT) Energy Consultancy (Gemserv), and most recently has worked with Software as a Service (SaaS) and biomedical start-ups. Her skills include strategy development & implementation, investment appraisals, contract negotiations and working capital management.



Robert Clements
Chief Commercial Officer

Over 30 years' experience in developing and delivering quality pharmaceutical sales, strategic marketing and business development across the sector. Wide-ranging, cross-functional skill set with an established record of high achievement and leadership on an international basis. A specialist in speciality pharma with multiple products launched in market. Very broad experience in nurturing KOL relationships, collaboration with partner companies/suppliers and developing international commercial footprint.



Itay Nissim
Chief Manufacturing and Supply Chain Officer

With a wealth of experience in multiple industries, from large scale agricultural rollouts to customer facing retail-oriented product development, Itay brings a focus on streamlining systems and creating efficient operations for MGC across the company's activities.



Dr. Nadya Lisodover
Chief Medical Officer

15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisovoder is a regulatory expert and has been clinical adviser to public biotech companies and a range of incubator and acceleration including Furtux- a J&J Innovation and Takeda program.



Amir Polak
Chief Research and Development Officer





20 years of experience in the fields of producing products from "Lab to the market". In his current position as CTO, Mr. Polak is managing MGC's production IMP facility in Slovenia – Producing Medicinal products for clinical trials and early access schemes.



Yair Tal
Chief Information Security Officer

A veteran of both the Israeli Security Agency and the Israeli Defense Forces, Yairs experience in security management, data protection and physical cyber security ensures MGC is operating at the highest level of security, from the company's facilities to it's online operations and most significantly, patient data.

Thank you
for your time and attention.

 info@mgcpharma.eu
 [@mgcpharmaceuticals](https://www.facebook.com/mgcpharmaceuticals)
 [@MGC_Pharma](https://twitter.com/MGC_Pharma)
 [MGC Pharmaceutical Ltd.](https://www.linkedin.com/company/mgc-pharmaceutical-ltd)

 mgcpharma.eu